These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33338491)

  • 21. Drug Distribution to Human Tissues: Prediction and Examination of the Basic Assumption in In Vivo Pharmacokinetics-Pharmacodynamics (PK/PD) Research.
    Poulin P
    J Pharm Sci; 2015 Jun; 104(6):2110-2118. PubMed ID: 25808270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction.
    Liu F; Zhuang X; Yang C; Li Z; Xiong S; Zhang Z; Li J; Lu C; Zhang Z
    Biopharm Drug Dispos; 2014 Jul; 35(5):296-307. PubMed ID: 24647883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Whole-Body Physiologically Based Pharmacokinetic Model for Colistin and Colistin Methanesulfonate in Rat.
    Bouchene S; Marchand S; Couet W; Friberg LE; Gobin P; Lamarche I; Grégoire N; Björkman S; Karlsson MO
    Basic Clin Pharmacol Toxicol; 2018 Oct; 123(4):407-422. PubMed ID: 29665289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction and lumping of physiologically based pharmacokinetic models: prediction of the disposition of fentanyl and pethidine in humans by successively simplified models.
    Björkman S
    J Pharmacokinet Pharmacodyn; 2003 Aug; 30(4):285-307. PubMed ID: 14650375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of volume of distribution in preclinical species and humans: application of simplified physiologically based algorithms.
    Nigade PB; Gundu J; Pai KS; Nemmani KVS; Talwar R
    Xenobiotica; 2019 May; 49(5):528-539. PubMed ID: 29771166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
    Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
    Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting Volume of Distribution in Neonates: Performance of Physiologically Based Pharmacokinetic Modelling.
    De Sutter PJ; Rossignol P; Breëns L; Gasthuys E; Vermeulen A
    Pharmaceutics; 2023 Sep; 15(9):. PubMed ID: 37765316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation and calibration of high-throughput predictions of chemical distribution to tissues.
    Pearce RG; Setzer RW; Davis JL; Wambaugh JF
    J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):549-565. PubMed ID: 29032447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical pharmacokinetics of MI-219, a novel human double minute 2 (HDM2) inhibitor and prediction of human pharmacokinetics.
    Zou P; Zheng N; Yu Y; Yu S; Sun W; McEachem D; Yang Y; Yu LX; Wang S; Sun D
    J Pharm Pharm Sci; 2012; 15(2):265-80. PubMed ID: 22579006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of human pharmacokinetics of typical compounds by a physiologically based method using chimeric mice with humanized liver.
    Nakayama K; Ito S; Suzuki M; Takubo H; Yamazaki H; Nomura Y
    Xenobiotica; 2019 Apr; 49(4):404-414. PubMed ID: 29619871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of unbound liver-to-plasma concentration ratio to quantitative projection of cytochrome P450-mediated drug-drug interactions using physiologically based pharmacokinetic modelling approach.
    Iwasaki S; Kosugi Y; Zhu AZX; Nakagawa S; Sano N; Funami M; Kosaka M; Furuta A; Hirabayashi H; Amano N
    Xenobiotica; 2019 Nov; 49(11):1251-1259. PubMed ID: 30516093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly protein-bound drugs and the impact of errors in plasma protein binding.
    Ye M; Nagar S; Korzekwa K
    Biopharm Drug Dispos; 2016 Apr; 37(3):123-41. PubMed ID: 26531057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A "middle-out approach" for the prediction of human drug disposition from preclinical data using simplified physiologically based pharmacokinetic (PBPK) models.
    Yau E; Gertz M; Ogungbenro K; Aarons L; Olivares-Morales A
    CPT Pharmacometrics Syst Pharmacol; 2023 Mar; 12(3):346-359. PubMed ID: 36647756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting volume of distribution with decision tree-based regression methods using predicted tissue:plasma partition coefficients.
    Freitas AA; Limbu K; Ghafourian T
    J Cheminform; 2015; 7():6. PubMed ID: 25767566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters.
    Kodaira H; Kusuhara H; Fuse E; Ushiki J; Sugiyama Y
    Drug Metab Dispos; 2014 Jun; 42(6):983-9. PubMed ID: 24644297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery.
    Poulin P; Theil FP
    J Pharm Sci; 2000 Jan; 89(1):16-35. PubMed ID: 10664535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In Silico Prediction of Pharmacokinetic Profile for Human Oral Drug Candidates Which Lack Clinical Pharmacokinetic Experiment Data.
    Zhai J; Ji B; Liu S; Zhang Y; Cai L; Wang J
    Eur J Drug Metab Pharmacokinet; 2022 May; 47(3):403-417. PubMed ID: 35171461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.
    Xia B; Heimbach T; Lin TH; He H; Wang Y; Tan E
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1567-82. PubMed ID: 22526410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Constraint-based perturbation analysis with cluster Newton method: a case study of personalized parameter estimations with irinotecan whole-body physiologically based pharmacokinetic model.
    Asami S; Kiga D; Konagaya A
    BMC Syst Biol; 2017 Dec; 11(Suppl 7):129. PubMed ID: 29322928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy.
    Pierrillas PB; Henin E; Ball K; Ogier J; Amiel M; Kraus-Berthier L; Chenel M; Bouzom F; Tod M
    Drug Metab Dispos; 2019 Jun; 47(6):648-656. PubMed ID: 30940629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.